Back to News
Market Impact: 0.15
Martin Shkreli violated lifetime pharma industry ban, FTC and states say in contempt claim
Source: CNBC
Legal & LitigationAntitrust & CompetitionRegulation & Legislation
Martin Shkreli was banned from the pharmaceutical industry after a trial found that he organized an illegal scheme to maintain a monopoly for Daraprim. The article provides no timing, financial figures, or current market reaction.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly negative
Sentiment Score
-0.30
More News
- US fines Bank of America $1.2bn for money laundering, sanctions violations
- Bank of America hit with more than $1.2 billion in penalties over money-laundering violations
- FBI arrests OpenAI employee accused of planting secret recording device in conference room
- Why is Bank of America stock sliding today?
- More Republicans come out against Trump's diesel deal with Putin
- Why this little known Chinese chipmaker has caused a global stock rout